Product Description
Mechanisms of Action: DNA Synthesis Inhibitor,DNA Gyrase Inhibitor,TOP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Ireland | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Osteomyelitis|Lyme Disease|Protein C Deficiency|Protein Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2022-06608 | P1 |
Recruiting |
Protein C Deficiency|Protein Deficiency|Lyme Disease |
2026-08-01 |
|
| PRESTO:Osteo | P1 |
Terminated |
Osteomyelitis |
2018-11-07 |